38 results
8-K
EX-99.1
BTAX
Biostax Corp.
2 Nov 23
Biostax Announces the Appointment of Ms. Mary Clay Caperton to its Board of Directors
9:00am
-looking statements), except as required by law. No assurances can be made that Immune will successfully acquire its acquisition targets. Forward
8-K
EX-99.1
BTAX
Biostax Corp.
24 Oct 23
Amendments to Articles of Incorporation or Bylaws
9:00am
. No assurances can be made that Immune will successfully acquire its acquisition targets. Forward-looking statements are subject to a number of factors
8-K
EX-99.1
BTAX
Biostax Corp.
20 Apr 23
Entry into a Material Definitive Agreement
9:00am
will successfully acquire its acquisition targets. Forward-looking statements are subject to a number of factors, risks, and uncertainties, some of which
8-K
EX-99.1
j079i9i19w4bjuye8b6o
9 Nov 22
Entry into a Material Definitive Agreement
5:00pm
8-K
EX-99.1
f50699dqhv
27 Sep 22
Immune Therapeutics Appoints H. Louis Salomonksy to its Board of Directors
2:37pm
8-K
EX-99.1
b5pn8d4iigkmy 27u
4 Aug 22
Immune Therapeutics Appoints Chief Financial Officer and Chief Operating Officer
1:00pm
8-K
EX-99.1
p3w80zstqr0z4tg
22 Jul 22
Immune Therapeutics, Inc. Appoints Dr. Stephen Wilson as Chief Executive Officer
3:44pm
DRS/A
xdu5hcjmla 4eh9qvd
14 Oct 16
Draft registration statement (amended)
12:00am
S-1
xzm099i
14 Oct 16
IPO registration
12:00am